Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 16, 2026Score 13/30231% above fair value
$112.00+6.96 (+6.63%)
Close on Nov 17, 2026Market cap $7.02BP/E –Yield –
Twist Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Twist Bioscience's operating cash flow for the twelve months ending Jun 30, 2026 was -$53.07M. For fiscal 2025 it was -$47.63M. The highest annual figure on record is -$47.63M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$47.63M | – |
| FY2024 | Sep 30, 2024 | -$64.09M | – |
| FY2023 | Sep 30, 2023 | -$142.47M | – |
| FY2022 | Sep 30, 2022 | -$124.39M | – |
| FY2021 | Sep 30, 2021 | -$112.24M | – |
| FY2020 | Sep 30, 2020 | -$142.26M | – |
| FY2019 | Sep 30, 2019 | -$87.94M | – |
| FY2018 | Sep 30, 2018 | -$66.16M | – |
| FY2017 | Sep 30, 2017 | -$51.30M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $1.12M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$17.56M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$24.81M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$11.81M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$1.40M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$12.99M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$21.43M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$15.32M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$6.38M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$19.42M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$22.97M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$20.70M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$23.41M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$44.29M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$54.07M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$1.27M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$34.13M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$42.34M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$46.65M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$34.80M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$27.96M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$24.55M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$24.93M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$25.20M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$23.47M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$58.67M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$34.91M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$23.36M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$22.08M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$20.81M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$21.68M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$16.70M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$16.94M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$16.51M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$16.02M | – |
See a number that looks wrong?